FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgAN Treatment
Vera Therapeutics announced FDA priority review for Atacicept's BLA to treat IgAN, with a target action date of July 7, 2026. CEO Marshall Fordyce highlighted its potential as a first-in-class B-cell modulator.